Shopping Cart
- Remove All
Your shopping cart is currently empty
SBI-115
🥰Excellent
Catalog No. T7428Cas No. 882366-16-7
SBI-115 is an antagonist of TGR5. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5
SBI-115
🥰Excellent
Purity: 99.53%
Catalog No. T7428Cas No. 882366-16-7
SBI-115 is an antagonist of TGR5. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $48 | In Stock | |
| 10 mg | $74 | In Stock | |
| 25 mg | $148 | In Stock | |
| 50 mg | $232 | In Stock | |
| 100 mg | $374 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $54 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "SBI-115"
Deoxycholic acid sodium salt
Sodium Desoxycholate, Sodium deoxycholate
T5077302-95-4
Deoxycholic acid sodium salt (Sodium deoxycholate) can activate the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
- $38
Size
QTY
Deoxycholic acid
Cited
Desoxycholic acid, Deoxycholate, DCA, Cholorebic, Cholerebic, Cholanoic Acid
T296583-44-3
Deoxycholic acid (Cholanoic Acid) is a bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
- $53
Size
QTY
CitedUrsodeoxycholic acid sodium
Ursodiol sodium, Ursodeoxycholic Acid (sodium salt), Ursodeoxycholate sodium, UDCA sodium, UDCA Na, Sodium Ursodeoxycholate
T290782898-95-5In house
Ursodeoxycholic acid sodium (Sodium Ursodeoxycholate) is a naturally occurring secondary bile acid with anti-inflammatory and cytoprotective activities. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors,
- $30
Size
QTY
Triamterene
SKF8542, Ademine
T0843396-01-0
Triamterene is a barosensitive epithelial sodium channel (ENaC) blocker with a diuretic effect. It can also act as an inhibitor of the TGR5 receptor, reducing GLP-1 secretion and cAMP level increases induced by TGR5 activation in a dose-dependent manner.
- $37
Size
QTY
TC-G 1005
T88181415407-60-1
TC-G 1005 is a potent and selective GPBA agonist (EC50 :0.72 nM; hTGR5). Selective for TGR5 over FXR (farnesoid X receptor). Increases plasma GLP-1 levels and reduces blood glucose in mice. Orally available.
- $30
Size
QTY
Hyodeoxycholic acid Cited
α-Hyodeoxycholic Acid, NSC 60672, HDCA
T296883-49-8
Hyodeoxycholic acid (NSC 60672) has been used in trials studying the treatment of Hypercholesterolemia.
- $38
Size
QTY
CitedL-692429
MK-0751
T11798145455-23-8In house
L-692429 (MK-0751) is a potent nonpeptidyl growth hormone secretagogue (GHS) agonist and benzolactam derivative, known for reversing glucocorticoid-induced inhibition of GH secretion. L-692429 exhibits high affinity for the G protein-coupled receptor and is useful in studying acromegaly and obesity.
- $158
Size
QTY
PEN (human) aceate
TP1949L
PEN (human) aceate, one of the most abundant hypothalamic neuropeptide and derived from the proprotein ProSAAS, is an endogenous ligand of GPR83.
- $148
Size
QTY
BAR501
BAR 501
T40831632118-69-4
BAR501 is an effective and specific GPBAR1 agonist (EC50: 1 μM).
- $44
Size
QTY
BAR502
TQ02521612191-86-2
BAR502 is a dual GPBAR1 and FXR agonist (IC50s: 0.4 μM and 2 μM).
- $64
Size
QTY
BAR 501 impurity
T87521632118-70-7
BAR501 impurity is an impurity found in the preparation of BAR501 that acts as an agonist of the G protein-coupled bile acid-activated receptor (GP-BAR1). BAR501 impurity (10 μM) induces a 150% increase in luciferase activity in a GP-BAR1 reporter gene assay
- $80
Size
QTY
Select Batch
Purity:99.53%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | SBI-115 is an antagonist of TGR5. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 |
| In vivo | Stimulation of cholangiocytes with TLCA following by SBI-115 treatment resulted in dose-dependent (by 32–48%) inhibition of cell proliferation. |
| Cell Research | cAMP was detected by the Bridge-It cAMP designer cAMP assay. Cholangiocytes (10,000/well) were incubated with TLCA, OA, C1 and C2 (all, 25 μM), SBI-115 (100 and 200 μM) and pasireotide (20 μM) for 15–30 min. Doses of drugs were chosen based on published data or dose ranging (SBI-115). Cell proliferation was determined by CellTiter 96 Aqueous One Solution Cell Proliferation Assay ?and by cell counting using the Cellometer Auto4 ?cell counter.?Cholangiocytes (2500 cells/well) were grown for 24–48 hours and then treated with TGR5 agonists (all, 25 μM), SBI-115 (100 and 200 μM) and pasireotide (20 μM) for additional 24 hours.?Alterations in cell proliferation after treatment were expressed as percent change compared to un-treated cholangiocytes in which cell proliferation was considered to be equal 100%. |
| Molecular Weight | 340.78 |
| Formula | C14H13ClN2O4S |
| Cas No. | 882366-16-7 |
| Smiles | CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1 |
| Relative Density. | 1.386 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (440.17 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy SBI-115 | purchase SBI-115 | SBI-115 cost | order SBI-115 | SBI-115 chemical structure | SBI-115 in vivo | SBI-115 formula | SBI-115 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.